Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × pembrolizumab × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9 Thoracic 8 Genitourinary 7 Gynecologic 6 Dermatologic 5 Head & Neck 3 Other solid neoplasm 2 Breast 2 Tumor-Agnostic 1 Sarcoma 1 NET 1 Lymphoid 1 Endocrine 1

Conditions

Interventions

trastuzumab deruxtecan 1 pembrolizumab 1 margetuximab 1 lenvatinib 1 larotrectinib 1 atezolizumab 1 Trastuzumab 1 Pemetrexed 1 Carboplatin 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Eisai Inc.

Phase 1/2 Completed

357 enrolled 28 charts 1 FDA

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡